The BioCentury 100 index is approaching its all-time high set at the peak of the hype-driven genomics bubble, thanks in large part to large cap performance.

The industry's resurgence has more fundamental underpinnings this time around. Nevertheless, one technical analyst thinks some big names might be ripe for near-term profit taking. But he thinks mid-caps could be poised for growth.